Publications by authors named "Amal Arahmani"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,675,320

Total Likes

57,610

Extended Reach

2,210,393

Social Features

151
A
Author Correction: Advancing equitable access to innovation in breast cancer.
Seamus O'Reilly, Ines Vaz Luis, Virginie Adam, Evangelia D Razis, Ander Urruticoechea, Amal Arahmani

NPJ Breast Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
Hans Wildiers, Virginie Adam, Seamus O'Reilly, Josephine Van Cauwenberge, Amal Arahmani

JAMA Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing equitable access to innovation in breast cancer.
Seamus O'Reilly, Ines Vaz Luis, Virginie Adam, Evangelia D Razis, Ander Urruticoechea, Amal Arahmani

NPJ Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.
Véronique Debien, Virginie Adam, Elisabeth Coart, Elisa Agostinetto, Theodora Goulioti, Amal Arahmani

Future Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
José Bines, Emma Clark, Claire Barton, Eleonora Restuccia, Marion Procter, Amal Arahmani

Br J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
José Bines, Marion Procter, Eleonora Restuccia, Giuseppe Viale, Dimitrios Zardavas, Amal Arahmani

Clin Breast Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.
Rina Hui, Alex Pearson, Javier Cortes, Christine Campbell, Camille Poirot, Amal Arahmani

Clin Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Amal Arahmani

N Engl J Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis